ABUS - Arbutus Biopharma Corp
4.29
-0.160 -3.730%
Share volume: 1,383,401
Last Updated: 03-27-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.18%
PREVIOUS CLOSE
CHG
CHG%
$4.45
-0.16
-0.04%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-02-2024 | 08-08-2024 | 11-06-2024 | 03-27-2025 | 05-14-2025 | 08-06-2025 | 11-13-2025 | 03-23-2026 | |
| Assets | |||||||||
| Total Assets | 150.290 M | 160.043 M | 140.441 M | 131.707 M | 117.010 M | 103.267 M | 97.710 M | 94.618 M | |
| Current Assets | 135.872 M | 148.220 M | 132.777 M | 127.316 M | 116.808 M | 103.119 M | 97.442 M | 94.456 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 86.139 M | 79.198 M | 95.948 M | 86.293 M | 75.631 M | 60.676 M | 71.294 M | 73.463 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 43.101 M | 62.788 M | 31.846 M | 36.330 M | 37.076 M | 37.412 M | 22.408 M | 18.008 M | |
| Total Non-current Assets | 8.677 M | 6.527 M | 2.964 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 4.414 M | 4.059 M | 3.556 M | 3.309 M | 168.000 K | 148.000 K | 137.000 K | 32.000 K | |
| Other Assets | 10.004 M | 7.764 M | 4.108 M | 1.082 M | 34.000 K | 0.000 | 131.000 K | 130.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 150.290 M | 160.043 M | 140.441 M | 131.707 M | 117.010 M | 103.267 M | 97.710 M | 94.618 M | |
| Total liabilities | 35.653 M | 37.589 M | 33.551 M | 34.341 M | 37.853 M | 20.291 M | 20.311 M | 18.042 M | |
| Total current liabilities | 20.296 M | 22.595 M | 18.923 M | 15.618 M | 19.431 M | 5.022 M | 5.184 M | 6.006 M | |
| Accounts Payable | 8.247 M | 11.108 M | 7.544 M | 7.564 M | 12.109 M | 4.508 M | 4.653 M | 5.459 M | |
| Other liabilities | 15.357 M | 14.994 M | 14.628 M | 15.860 M | 15.559 M | 15.269 M | 15.127 M | 12.036 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 15.357 M | 14.994 M | 14.628 M | 15.860 M | 15.559 M | 15.269 M | 15.127 M | 12.036 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 114.637 M | 122.454 M | 106.890 M | 97.366 M | 79.157 M | 82.976 M | 77.399 M | 76.576 M | |
| Common stock | 1.458 B | 1.485 B | 1.489 B | 1.492 B | 1.498 B | 1.500 B | 1.502 B | 1.505 B | |
| Retained earnings | -1.295 B | -1.314 B | -1.334 B | -1.347 B | -1.371 B | -1.369 B | -1.376 B | -1.380 B |